Vanda Pharmaceuticals Q4 EPS $0.15 Beats $0.14 Estimate, Sales $67.70M Beat $64.00M Estimate
Vanda Pharmaceuticals Q4 EPS $0.15 Beats $0.14 Estimate, Sales $67.70M Beat $64.00M Estimate
Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.14 by 7.14 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $67.70 million which beat the analyst consensus estimate of $64.00 million by 5.78 percent. This is a 11.11 percent increase over sales of $60.93 million the same period last year.
Vanda Pharmaceuticals (NASDAQ:VNDA) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0.14 by 7.14 percent. This is a 87.5 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $67.70 million which beat the analyst consensus estimate of $64.00 million by 5.78 percent. This is a 11.11 percent increase over sales of $60.93 million the same period last year.
萬達製藥(納斯達克:VNDA)公佈的季度收益為每股0.15美元,比分析師普遍預期的0.14美元高出7.14%。這比去年同期每股0.08美元的收益增長了87.5%。該公司公佈的季度銷售額為6770萬美元,比分析師一致預期的6400萬美元高出5.78%。這比去年同期6093萬美元的銷售額增長了11.11%。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧